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Abstract
Background: Q fever is a zoonosis that is present in many countries. Q fever fatigue syndrome (QFS) is one of the
most frequent sequelae after an acute Q fever infection. QFS is characterized by persistent fatigue following an
acute Q fever infection, leading to substantial morbidity and a high socio-economic burden. The occurrence of QFS
is well-documented, and has been described in many countries over the past decades. However, a treatment with
proven efficacy is not available. Only a few uncontrolled studies have tested the efficacy of treatment with
antibiotics on QFS. These studies suggest a positive effect of long-term treatment with a tetracycline on
performance state; however, no randomized controlled trials have been performed. Cognitive behavioral therapy
(CBT) has been proven to be an effective treatment modality for chronic fatigue in other diseases, but has not yet
been tested in QFS. Therefore, we designed a trial to assess the efficacy of long-term treatment with the
tetracycline doxycycline and CBT in patients with QFS.
Methods/design: A randomized placebo-controlled trial will be conducted. One-hundred-eighty adult patients
diagnosed with QFS will be recruited and randomized between one of three groups: CBT, long-term doxycycline or
placebo. First, participants will be randomized between CBT and medication (ratio 1:2). A second double-blinded
randomization between doxycycline and placebo (ratio 1:1) will be performed in the medication condition. Each
group will be treated for six months. Outcome measures will be assessed at baseline and post intervention. The
primary outcome measure is fatigue severity. Secondary outcome measures are functional impairment, level of
psychological distress, and Coxiella burnetii PCR and serology.
Discussion: The Qure study is the first randomized placebo-controlled trial, which evaluates the efficacy of long-
term doxycycline and of cognitive behavioral therapy in patients with QFS. The results of this study will provide
knowledge about evidence-based treatment options for adult patients with QFS.
Trial registration: ClinicalTrials.gov: NCT01318356, and Netherlands Trial Register: NTR2797
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Background
Q fever, a zoonosis caused by Coxiella burnetii, has been
present all over the world for many years [1]. Between
2007 and 2010, the south-eastern part of the Netherlands
has faced the largest outbreak of Q fever ever reported.
To date, more than 4000 people have developed symp-
tomatic disease [2], and at least up to 44,000 are estimated
to have been infected [3,4]. In recent years, several studies
have described the sequelae of Q fever. Acute Q fever is
followed by a chronic infection in 1-5% of cases [5-7]. In
addition, following acute Q fever, patients frequently re-
port long-lasting fatigue, which often persists for more
than six months [8-10]. After an outbreak of Q fever in
the UK, 10 years of follow-up revealed a high percentage
of persisting fatigue, with almost 20% of patients fulfilling
the Centre for Disease Control (CDC) criteria of chronic
fatigue syndrome, compared to 4% in healthy controls
[11]. A study among abattoir employees in Australia
showed that 28% of patients with proven acute Q fever
fulfilled the CDC criteria of chronic fatigue syndrome five
years after the infection compared to none of the sero-
negative controls [10]. A recent study carried out in the
Netherlands among 85 patients with acute Q fever found
that 59% of patients had persistent symptoms at six
months after disease onset, with fatigue being the most
prevalent complaint in 52% of patients. Furthermore, over
25% still had complaints after one year [12]. Another re-
cent survey in the Netherlands among 515 patients with
Q fever found that 20% had severe fatigue and an im-
paired health status at 12–26 months of follow-up [13].
This fatigue following acute Q fever, sometimes accom-
panied by several other complaints, has been designated
Q fever fatigue syndrome (QFS) [14-16]. According to the
recently published Dutch algorithm on QFS [14], the diag-
nosis of QFS can be made after a uniform diagnostic
work-up. There has to be a severe fatigue, which lasts for
at least six months and has a reference to an acute Q fever
infection. There must be an absence of fatigue before the
episode of acute Q fever or a significant increase in fatigue
since the acute Q fever infection. Furthermore, it is caus-
ing significant disabilities in daily practice. Finally, chronic
Q fever and other causes of fatigue, somatic or psychiatric,
need to be excluded.
In the Netherlands, QFS resulted in a large incurred
loss due to loss of quality of life and health-related ab-
senteeism in the past few years [17]. Currently, extrapo-
lating the present data, at least 800 patients suffer from
QFS in the Netherlands. It is expected that Q fever will
remain an endemic disease, leading to a further increase
in patients with QFS, stressing the need for further re-
search into treatment regimens for QFS.
Both acute and chronic Q fever have been extensively
studied in recent years; however, less attention has been
given to QFS. Although QFS is a well documented
finding and has already been described in 1996 [8,10], at
present there is no consensus on the pathogenetic
process underlying QFS [15,18,19]. In QFS, as in chronic
fatigue syndrome, persistence of live microbes has been
suggested [19]. Furthermore, it is still unclear whether
effective treatment for QFS is possible. So far, few stud-
ies on the effect of treatment with antibiotics on fatigue
after Q fever have been done. The available studies sug-
gest a positive effect of long-term treatment with a tetra-
cycline on performance status [20-22]; however, these
studies suffer from several limitations. So far, no con-
trolled trials have been performed and the above long-
term treatment is currently not often used in clinical
care of patients with QFS. Previously, it has been shown
in patients with chronic fatigue syndrome (CFS) that
fatigue-related cognitions and behavior can maintain
chronic fatigue [23-26]. CBT for chronic fatigue is aimed
at these fatigue-related cognitions and behavior thought
to perpetuate the symptoms. Several systematic reviews
and meta analyses demonstrated that CBT for CFS is
able to reduce symptoms and to improve function in pa-
tients with CFS [26-28]. To date, the efficacy of CBT has
not been studied in patients with QFS. However, our re-
cent clinical experience with this treatment modality in
a small cohort of QFS patients shows promising results.
The primary aim of our study is to determine the ef-
fect of different treatment modalities which have been
suggested to be effective for patients with QFS. In this
paper we describe the protocol to assess the efficacy of
two treatment strategies for QFS: long-term treatment
with either doxycycline or CBT.
Methods/design
Study design
A randomized placebo-controlled trial (RCT), the Qure
study, will be performed to determine whether long-
term treatment with doxycycline or CBT will lead to a
reduction of fatigue and disabilities in patients with
QFS. Both treatment modalities will be compared to a
placebo group. This study will be performed in the
Radboud University Nijmegen Medical Centre in the Q
fever outpatient clinic of the department of Internal
Medicine, and in the Expert Centre for Chronic Fatigue
(ECCF). QFS will be diagnosed at the Q fever outpatient
clinic after a uniform diagnostic work-up according to
the Dutch algorithm on QFS. Once the diagnosis is
established, study eligibility will be assessed by the first
author (SPK) according to specific inclusion and exclu-
sion criteria (Tables 1 and 2). Eligible patients will be
asked to participate in the Qure study after receiving
verbal and written information about the study. If pa-
tients are willing to participate, written informed con-
sent will be obtained. After inclusion, an individual
study code is allocated to the participants. Results from
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the clinical assessment before inclusion will be used as
baseline measures as well. If patients decide not to par-
ticipate in this study, an attempt will be made to eluci-
date the reason for this, but patients are not obligated to
motivate their refusal.
Study population
It is intended to include 180 patients diagnosed with QFS,
equally randomized between three different treatment
modalities, namely long-term doxycycline (n = 60), CBT
(n = 60) or placebo (n = 60). All eligible patients directly
referred to Radboud University Nijmegen Medical Centre
will be asked to participate in this study. Patients with a
suspicion of QFS presenting to other hospitals in the area
will be referred to the Q fever outpatient clinic of the
Radboud University Nijmegen Medical Centre for screen-
ing and enrollment in the study. In addition, all physicians
working at specific Q fever outpatient clinics in other hos-
pitals will be informed about the study. Patients connected
to Q-uestion, a foundation for patients with Q fever, will
be informed about the Qure study by newsletters, and a
brief description will be available at the website of Q-
uestion. Furthermore, patients who participated in previ-
ous studies on Q fever in the past few years (Q-Quest II
study, ZonMw dossier number: 204004003, and The
PrediQt study, ZonMw dossier number: 205520003,
NL36477.091.11), will be informed about the Qure study
by letter. Finally, all general practitioners in the endemic
Q fever region will be informed about this study by letter.
Ethical approval
According to the Dutch law, this study has been reviewed
and approved by the Medical Ethical Review Committee
of the Radboud University Nijmegen Medical Centre
(registration number 2011/069, NL35755.091.11). This
study will be conducted according to the principles of the
Declaration of Helsinki. The inclusion of patients started
in May 2011.
Baseline assessment
After inclusion, participants will first visit the ECCF for the
baseline assessment, including questionnaires and mea-
surement with an actometer (see Figure 1). An actometer
is a motion-sensing device worn at the ankle that registers
and quantifies physical activity. The actometer has a piezo-
electric sensor that is sensitive in three directions. Accele-
rations of the built-in sensor larger than a predefined
threshold are considered as activity and are stored in an in-
ternal memory every 5 minutes. It is worn day and night
during a period of twelve consecutive days [31]. A general
physical activity score that expressed the mean activity
level over this period in the mean number of accelerations
per 5 minute interval will be calculated. During the period
of twelve days participants rate fatigue, pain, and activity
levels on a pre-scheduled Self-Observation List four times
daily on a scale of 0 (not at all) to 4 (very much).
Table 1 Inclusion criteria
Inclusion criteria*
(1) Males or non-pregnant, non-lactating females who are 18 years
or older
(2) Laboratory-proven acute Q fever since the year 2007 and/or
positive serology fitting a past infection with Coxiella burnetii
(3) AND being severely fatigued, defined by scoring ≥ 35 on the
subscale fatigue severity of the CIS
(4) AND being fatigued for at least 6 months
(5) AND being disabled because of the fatigue, defined by scoring
450 or higher on the SIP
(6) Subject must sign a written informed consent form
* All participants have to meet the criteria for QFS according to the recently
published Dutch algorithm on QFS [14]. In addition to the mentioned
inclusion criteria and according to the Dutch algorithm on QFS, there has to
be a severe fatigue with a reference to an acute Q fever infection.
Furthermore, there must be an absence of fatigue before the episode of acute
Q fever or a significant increase in fatigue since the acute Q fever infection.
Abbreviations: CIS = Checklist Individual Strength questionnaire, SIP = Sickness
Impact Profile questionnaire.
Table 2 Exclusion criteria
Exclusion criteria
(1) Fulfilling criteria for chronic Q fever*
(2) Acute Q fever in the setting of a prosthetic cardiac valve or
aneurysm surgery or stenting, necessitating prophylactic use of
doxycycline
(3) Pregnancy or unwillingness to use effective contraceptives
during the entire study period
(4) Imminent death
(5) Inability to give informed consent
(6) Allergy or intolerance to doxycycline
(7) Somatic or psychiatric illness that could explain the chronic
fatigue
(8) Subjects who are currently enrolled in other investigational drug
trials or receiving investigational agents
(9) Receiving or having received antibiotics for > 4 weeks,
potentially active against Coxiella burnetii, for any other reason
since Q fever diagnosis
(10) Subjects who are receiving and cannot discontinue barbiturates,
phenytoin, or carbamazepine**
(11) Moderate or severe liver disease (AF, ALT, AST > 3 times the
upper limit of normal)
(12) Current engagement in a legal procedure concerning financial
benefits#
* According to the guideline chronic Q fever from the Dutch Q fever consensus
group [29].
** These drugs may increase the metabolism of doxycycline; consequently,
reducing the half-life of doxycycline.
# Temporary exclusion criterion, while current involvement interferes with the
effectivity of cognitive behavioral therapy [30]. Once the appeal procedure
ends, subjects can be included.
Abbreviations: AF = alkaline phosphatase, ALT = alanine aminotransferase,
AST = aspartate aminotransferase.
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Randomization procedure and blinding
The randomization order is created by an independent
biostatistician using block-randomization. An administra-
tive assistant with no affiliation to the project group made
envelopes for individual study codes ranging from 1–180,
according to the randomization list. At the end of the first
visit to the ECCF, participants receive their envelope
(which contains a corresponding number coherent to the
individual study code) from the psychological assistant, to
see to which treatment they are randomized. First, partici-
pants will be randomized between CBT and medication
(ratio 1:2). Secondly, double-blinded randomization be-
tween doxycycline treatment or placebo (ratio 1:1) will be
performed within the medication condition by the study
pharmacist (department of Clinical Pharmacy, Radboud
University Nijmegen Medical Centre). The double-blinded
randomization assignment will be known to the study
pharmacist only, and is available in a sealed envelope
stored at the pharmacist’s office for emergency use. If the
code is broken, it will render the participant not eligible.
The first randomization list and second double-blinded
randomization list will be made available respectively by
the independent biostatistician and the study pharmacist
to the principal investigator when the entire study is com-
pleted. Obviously, allocation to the CBT intervention can-
not be blinded.
Interventions
Study medication
Preparation and labeling of doxycycline and placebo will be
performed by the Clinical Trials Unit department of the
Clinical Pharmacy of the Radboud University Nijmegen
Placebo
once daily
Screening and recruitment
(outpatient clinic)
Inclusion
Baseline assessment and 
randomization (ECCF)
Second assessment 
(ECCF)
CBT group
(ECCF)
Medication group 
(outpatient clinic)
Protocolized 
interventions of 
12-14 sessions of 
CBT during a period 
of 24 weeks
Double-blind randomization 
Two weeks
Clinical assessment* 
Questionnaires**, 
actigraphy and sleep-wake 
pattern registration
Doxycycline
once daily 200mg
24 weeks after start treatment: 
End-of-therapy study visit
4 weeks after start treatment: evaluation of side effects and 
laboratory control
8 weeks after start treatment: evaluation of side effects, level of 
doxycycline, mediation analysis# and laboratory control
16 weeks after start treatment: evaluation of side effects and 
laboratory control
8 weeks after start 
CBT: mediation 
analysis#
Questionnaires^, 
actigraphy and sleep-wake 
pattern registration
26 weeks after start treatment: 
End-of-study visit 
(outpatient clinic)
Exclusion 
criteria¥
Coxiella serology 
and PCR
Figure 1 Flowchart of trial design. * According to the Dutch guideline Q fever fatigue syndrome [14]. Including questionnaires: general
questionnaire, CIS, SIP total score. ** General questionnaire, PARS, SES28, IMQ, CBRSQ, JFCS, CAL, and SCL90. # Questionnaires used for
mediation analysis: PARS, SES28, IMQ, CBRSQ, and CIS. ¥ Exclusion criteria: pregnancy; serious adverse events; AST/ALT > 5 times normal value;
AF > 3 times normal value; > 10 days use of quinolon, co-trimoxazol, macroliden or tetracycline; or discontinuation of study medication > 7
consecutive days. ^ CIS, PARS, IMQ, JFCS, SIP, SES28, CBRSQ, and SCL90. Abbreviations: CIS = Checklist Individual Strength, SIP = Sickness Impact
Profile, ECCF = Expert Centre for Chronic Fatigue, PARS = Physical Activity Rating, SES28 = Self Efficacy Scale, IMQ = Symptom focusing of the
illness Management Questionnaire, CBRSQ = Cognitive and Behavioral Responses to Symptoms Questionnaire, JFCS = Jacobson Fatigue
Catastrophising Scale, CAL = Causal Attribution List, SCL90 = Symptom Checklist 90, CBT = cognitive behavioral therapy, AST = aspartate
aminotransferase, ALT = alanine aminotransferase, AF = alkaline phosphatase.
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Medical Centre, and will be done according to the relevant
Good Manufacturing Practice (GMP) guidelines. Study
medication will be prepared as capsules with identical ap-
pearance. Participants allocated to study medication will be
treated at the Q fever outpatient clinic. Participants will
receive either doxycycline (200 mg once daily) or placebo
(once daily), both orally administered, for a period of 24 -
weeks. Study medication will be provided by the first
author (SPK). For safety considerations all participants in
the medication condition will visit the Q fever outpatient
clinic 4, 8, and 16 weeks after start of the treatment (see
Figure 1). Furthermore, liver enzymes will be checked, and
drug utilization will be recorded. Therefore, patients are
required to bring the study medication to all visits. In
addition, blood samples drawn 8 weeks after start of treat-
ment will be stored by the study pharmacist, who per-
formed the double-blinded randomization. Eventually,
doxycycline levels will only be determined in participants
receiving doxycycline, and results will be kept secret until
the entire study is completed. After completion, it is
known whether doxycycline levels were sufficient to sort
out effect [32]. Participants will be excluded in case of:
serious side effects; aspartate aminotransferase (AST)/ala-
nine aminotransferase (ALT) levels more than 5 times the
upper limit of normal; alkaline phosphatase (AF) levels
more than 3 times the upper limit of normal; more than
10 days use of antibiotics potentially active against C.
burnetii (co-trimoxazol, quinolon, macrolides or tetracy-
clines); or discontinuation of study medication for more
than 7 consecutive days.
Cognitive behavioral therapy
CBT for QFS is aimed at changing the beliefs and behav-
iors assumed to maintain fatigue. On average, CBT con-
sists of 12–14 sessions over a period of 24 weeks, and is
individually delivered by trained cognitive-behavioral
therapists from the ECCF, according to a written treat-
ment manual. The treatment is based on CBT for CFS
[33]. First, the model of fatigue perpetuating beliefs and
behaviors is explained to patients. At the start of the
therapy patients formulate their goals in behavioral
terms. These goals usually include the resumption of
work, hobbies, and other activities that imply that the
patient is no longer severely fatigued and disabled, which
is the goal of CBT for QFS. Patients regulate their bed-
times and stop sleeping during the day in order to stop
possible disruption of the circadian rhythm. During the
sessions, the therapist elicits and challenges patients’
non-accepting and catastrophising beliefs with respect to
fatigue. Additionally, patients are taught how to distract
their attention from their fatigue. Two groups of patients
are discerned: relatively active patients, who are character-
ized by bursts of activity followed by periods of relative in-
activity, and low active patients, who have extremely low
activity levels on most days [31]. Relatively active patients
first learn how to divide their activities more evenly across
the day. Low active patients start with a graded activity
program immediately after the initial cognitive interven-
tions. This activity program consists of daily walking or
cycling, which is gradually increased. The increase in ac-
tivity is not determined by the level of symptoms, but is
time contingent. When patients succeed in increasing
their physical activity, they also start to increase their so-
cial and mental activities. In the last phase of therapy, pa-
tients work systematically towards reaching their goals,
which are formulated at the start of the therapy. Following
this, they are encouraged to perceive feelings of fatigue as
a normal part of an active and healthy life.
Post intervention
Twenty-four weeks after start of treatment, all participants
visit the ECCF for the end-of-therapy study visit, including
assessment of the outcome measures (see Figure 1).
Twenty-six weeks after start of treatment, participants
visit the Q fever outpatient clinic for the end-of- study
visit. During this end-of-study visit, C. burnetii serology
and PCR will be determined.
Outcome measures
The primary outcome measure is the fatigue severity
measured by the subscale fatigue severity (8 items, 7-
point Likert Scale) of the Checklist Individual Strength
(CIS questionnaire) [34] with a severity range from 8–
56. High scores indicate a high level of fatigue. Patients
with a cut-off score of ≥35 are classified as severely fa-
tigued. This questionnaire has excellent psychometric
properties, including good reliability and discriminative
validity [35,36].
Secondary outcome measures are:
(1)Level of functional impairment measured with the
Sickness Impact Profile (SIP) [37,38]. The SIP is an
instrument that is used to gauge sickness-related
dysfunction. The weighted total score on eight sub-
scales of the SIP8 (SIP8 total score) will be used to
assess functional disability in all domains of
functioning. This instrument is reliable with
sufficient content validity, and it shows good
correlations with other health status and functional
status measures [39].
(2)Level of psychological distress measured with the
total score of the Symptom Checklist 90 (SCL90).
The SCL90 consist of 90 items scored on a five-
point scale. Scores range from 90–450. A low total
score reflects psychological well-being. The SCL-90
is a reliable and valid instrument [40].
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(3)C. burnetii serology (immunofluorescence assay;
Focus Diagnostics, Inc., Cypress, CA, USA) and
serum PCR.
Other study parameters will be: demographic data;
data on symptoms, diagnosis and treatment of acute Q
fever; previous history; serology results performed before
inclusion in the study; use of medication, smoking, and
the use of alcohol or drugs; and data on self reported
symptoms, disabilities, and behavioral factors.
Mediation analysis
Testing mediation is a strategy to identify variables that
intervene in the relationship between treatment and out-
come. Mediation analysis can help to better understand
how treatment works [41]. To assess a change in variables
that might affect fatigue severity, possible mediators and
fatigue severity will be assessed at baseline, eight weeks
after start of treatment, and at end of therapy in all treat-
ment modalities (see Figure 1). The proposed mediators
are fatigue related cognitions and behaviors. Four instru-
ments will be used to assess the mediators: 1) Subscales
‘resting/avoidance’, ‘all-or-nothing’ behavior, and ‘catastro-
phising’ of the Cognitive Behavioral Responses to Symp-
toms Questionnaire (CBRSQ) [42], 2) Subscale focusing
on symptoms of the Illness Management Questionnaire
(IMQ) [43,44], 3) Total score on the Physical Activity
Rating Scale (PARS, measuring the level of confidence and
expectation on fatigue performing 16 different activities,
rated on a five-point scale), and 4) Total score on the Self
Efficacy Scale (SES28) [45].
Withdrawal of individual participants
Participants are informed that they can stop participa-
ting in the study at any time, without consequences. Al-
though participants will be asked for the reason for
discontinuation, giving a reason for withdrawal is not
obligatory. The investigator can decide to withdraw a
participant from the study in case of medical urgency. In
addition, study medication will be stopped in case of
pregnancy, and the participant will be withdrawn.
According to the Intention To Treat (ITT) principle the
analysis will be based on the initial treatment intent.
Therefore, in case of discontinuation, all efforts will be
made to complete and report the observations as thor-
oughly as possible. A complete final evaluation in ac-
cordance to the study protocol end-of-therapy study
visit will be performed if the withdrawn participant
agrees. Because of absence of an evidence-based treat-
ment for QFS, other treatment options for QFS in regular
health care for withdrawn participants in the CBT group
are not available. Long-term doxycycline treatment is not
offered, because of possible (serious) side-effects and a
lack of evidence so far.
Adverse events
Adverse events are defined as any undesirable experience
occurring to a subject during the study, whether or not
considered related to the experimental treatment. All ad-
verse events in the medication condition will be recorded
during the pre-scheduled controls at the outpatient clinic,
and, if applicable, during the trial if spontaneously re-
ported by the participant. The most frequent side-effects
of doxycycline include gastrointestinal complaints, like
nausea and diarrhea, and photo-sensibilisation. Other
side-effects are rare. The drug should not be given to chil-
dren and to pregnant women. This RCT involves a non-
critical indication for the use of doxycycline, and the drug
under investigation is well characterised and commonly
used in daily practice. Even though the delivery of CBT to
adults is considered safe [46,47], all adverse events reported
spontaneously by the participant or observed by the therapist
will be recorded by the psychological assistant at pre-
scheduled time-points during the therapy (8 weeks after the
start of therapy, and 24 weeks after start of therapy). All
adverse events will be followed until they have abated, or
until a stable situation has been reached. If applicable, serious
adverse events in both groups will be reported according to
the principles of Good Clinical Practice (GCP).
Statistical analysis
The primary analysis will be the comparison between
the experimental groups (CBT or doxycycline) and the
placebo group. ITT will be the basis for all analysis. The
primary analysis will be done on the data of completers.
Completers are all participants who completed the post
intervention measurements. When statistical significant
differences are found, a sensitivity analysis will be
performed on the basis of different assumptions about
the values of missing data. To determine if there is a sig-
nificant difference between the intervention arm and
placebo condition, ANCOVA will be used with the out-
come measure on the second assessment as dependent
measure, the baseline score as covariate, and condition
as fixed factor. A priori contrasts will be defined for the
factor condition comparing CBT versus placebo, and
comparing doxycycline versus placebo. For the second-
ary outcome measures, namely psychological distress
and functional limitations, the same analysis will be re-
peated, but with the secondary outcome measures at the
second assessment as dependent variable, and the scores
at baseline as covariate. In this kind of trials ANCOVA
yields greater power than other statistical methods [48].
Statistical significance will be assumed at p < 0.05 in all
analysis. Data will be presented as quantitative results.
Power calculation
The power calculation is based on the estimated max-
imal number of eligible patients who will be available for
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the study. In the Netherlands there has been only one
major outbreak of Q-fever. Since then, the number of
new cases is limited. Furthermore, following the out-
break several studies investigating the symptoms follow-
ing Q-fever are ongoing which limits the number of
eligible patients that will be available to enter the present
study. The maximal number of available patients is esti-
mated to be 180, 60 patients for each arm of the study.
We assumed a drop-out rate of 20 percent, leaving a
sample size for the power calculation of 50 participants
per arm. Compared to a t-test, using ANCOVA increases
statistical power. The sample size of 50 can be divided
by a design factor of 0.884 (1–0.342), with 0.34 being the
correlation between the CIS fatigue severity at baseline
and second assessment [49]. The required effect size was
estimated using G-Power 3.1.5. based on a sample size
of 56, a power of 0.80 and an alpha of 0.05. The analysis
showed that we need to assume a moderate controlled
effect size of 0.53 to obtain a power of 0.8 for demon-
strating a significant difference between the results in
the treatment groups and in the placebo group.
Discussion
The Qure study will be the first randomized placebo-
controlled clinical trial to assess the efficacy of long-term
treatment with doxycycline and CBT in adult patients
with QFS. A limited amount of previous uncontrolled
studies suggest a positive effect of long-term treatment
with a tetracycline on performance state. The result of
one study shows improvement in symptoms, including fa-
tigue, in all patients after 3 months of treatment. However,
not all patients met the current criteria for QFS, whereas
7 patients were PCR positive, meeting the current criteria
for chronic Q fever [20]. Furthermore, patients were in-
cluded with complaints lasting for only 3 months, whereas
chances for spontaneous recovery are high in the first 6 -
months after the initial infection. The other study, pri-
marily focussing on the role of C. burnetii in CFS,
reports improvement in performance status, a decreased
mean headache score, and a decrease in mean weekly
temperature after treatment [21]. However, of the 54 pa-
tients included, 34 patients were PCR positive at base-
line, suggesting chronic Q fever. Furthermore, patients
were included with complaints lasting for only 1 month.
Therefore, these results cannot be extrapolated, and this
long-term treatment is currently not often used in clin-
ical care of patients with QFS. Furthermore, the efficacy
of CBT in patients with QFS has not been evaluated in a
randomized design. Currently, the decision whether or
not to treat is made arbitrarily, as evidence-based strat-
egies are lacking. The Dutch outbreak offers us a great
and maybe the only opportunity to conduct research on
the best treatment of QFS.
In conclusion, the Qure study will provide greater insight
into effectiveness of treatment options for adult patients
with QFS. If an effective treatment modality for QFS will be
found, significant benefit can be achieved in quality of life,
efficiency in treatment and cost-effectiveness. Furthermore,
this study will possibly contribute to the establishment of
evidence-based guidelines for the treatment of QFS.
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